The $800 Million Lifeline: Iluvatar CoreX’s Hong Kong IPO and the Last Stand of Chinese GPU Ambition

On a quiet Tuesday morning, a filing landed on the Hong Kong Stock Exchange’s server. It wasn’t a DeFi protocol or a Layer-2 scaling solution—it was a GPU company called Iluvatar CoreX, and it was asking for $800 million. In the bear market of 2026, that number echoes like a gunshot in a cathedral. The market has seen ICOs, NFTs, and AI agents try to raise similar sums, but rarely from a chip designer that hasn't shipped a single profitable product. People first, protocol second. Always. But here, the protocol is a chip architecture, and the people are the engineers trapped between national ambition and capitalist reality.

Iluvatar CoreX—known in Chinese as Biren Technology—is a Shanghai-based GPGPU startup that once promised to be China’s answer to NVIDIA. Its flagship BR100 chip, built on TSMC’s 7nm process with 770 billion transistors, was unveiled in 2022 with fanfare. The company boasted performance rivaling NVIDIA’s A100 in AI training workloads. But that was before the U.S. Department of Commerce added Iluvatar to the Entity List in October 2022, cutting off its access to TSMC’s advanced nodes and critical EDA tools. Since then, the company has been a ghost—existing on paper, burning cash, and clinging to a single customer: ByteDance.

Now, Iluvatar is seeking an $800 million IPO in Hong Kong. The timing is curious. The global semiconductor market is in a downcycle, AI chip hype is cooling, and geopolitical tensions are at a fever pitch. But for Iluvatar, this isn’t a growth story—it’s a survival story. Based on my audit experience during the 2017 ICO boom, I’ve seen companies raise massive sums on thin promises. The difference here is that Iluvatar has real hardware, real talent, and a real customer. But it also has a real prison: the Entity List.

Context: The BR100 Dream and the Sanctions Shock

To understand the IPO, you must first understand the chip. The BR100 is a general-purpose GPU designed for AI training and inference. It uses a custom architecture called “Bili Ren” (壁立仞), supports CUDA-like programming models, and integrates 32GB of HBM2e memory via CoWoS 2.5D packaging. In benchmarks, it achieved 1000 TFLOPS of FP16 compute—close to the NVIDIA A100’s 312 TFLOPS FP16 (with sparsity), but Iluvatar’s numbers were real. The chip was taped out in 2021 and began sampling to select customers in 2022.

Then came the Entity List. The U.S. Bureau of Industry and Security (BIS) added Iluvatar alongside other Chinese chip firms, citing national security concerns. The immediate impact: TSMC could no longer manufacture BR100 or any future designs below 14nm. All advanced packaging (CoWoS) stopped. EDA vendors like Cadence and Synopsys suspended support. Iluvatar was cut off from the global supply chain that made its existence possible.

The company’s response was to pivot. It announced a partnership with domestic foundry SMIC to port its designs to 14nm. But anyone who understands chip design knows this isn’t a simple recompile. The BR100’s architecture was optimized for 7nm high-performance libraries. Porting to 14nm would reduce clock speeds by 30-40%, increase power consumption, and require extensive redesign. At best, Iluvatar could produce a “BR100 Lite” with 40% of the original performance. At worst, the whole effort could fail.

ByteDance, the parent company of TikTok and Douyin, became Iluvatar’s lifeline. In 2023, ByteDance reportedly placed orders worth hundreds of millions of dollars for Iluvatar’s chips, using them in its AI data centers as a backup to NVIDIA and Huawei. But this is a precarious bridge. ByteDance’s commitment is not based on love—it’s based on supply chain diversification and Chinese government pressure. If Huawei’s Ascend 910B or newer products deliver better performance, ByteDance will switch in a heartbeat.

Now the IPO: $800 million at a valuation that insiders whisper could exceed $5 billion. For a company that has never reported a profit, this is a massive ask. But it’s also a chance to refill the war chest before the cash runs out.

Core: The Technology Trap and the Ecosystem Cliff

Let’s get technical. The BR100 is not a bad chip. Its 770 billion transistors, 7nm process, and CoWoS packaging put it in the same league as NVIDIA’s A100 (54 billion transistors on 7nm) and AMD’s MI250. But transistor count alone doesn’t win. NVIDIA’s dominance comes from CUDA—a software ecosystem that took 15 years and billions of dollars to build. Iluvatar’s “Bili” software stack is a clone of CUDA, but compatibility is incomplete. Developers report that porting PyTorch models to Iluvatar requires manual optimization, and performance often degrades by 20-30% compared to native NVIDIA hardware.

This is the ecosystem cliff. In AI, hardware is a commodity; software is the moat. Even if Iluvatar could manufacture its chips at scale, it would struggle to win customers beyond ByteDance because every AI engineer knows CUDA. The switching cost is enormous. Iluvatar’s only hope is to become “good enough” for inference workloads, where performance requirements are lower and price sensitivity is higher. But inference is a razor-thin margin business dominated by Intel, AMD, and a swarm of startups.

Meanwhile, the supply chain vulnerability is existential. Iluvatar relies on SMIC for 14nm production, but SMIC itself is under U.S. sanctions that limit its ability to acquire EUV lithography. SMIC’s 14nm yields are reportedly low (around 50-60% vs. 90%+ for TSMC). This means Iluvatar’s production costs are high, and output is constrained. The $800 million IPO will likely go toward pre-paying SMIC for capacity and stockpiling HBM2e memory from Samsung—which is also subject to export controls.

But the deepest hidden message is this: Iluvatar is not building for the global market. It’s building for the Chinese government’s “Xinchuang” (indigenous innovation) initiative. The real customer isn’t ByteDance; it’s the Ministry of Industry and Information Technology. The real product isn’t the chip; it’s the story of self-reliance. And stories have valuations, but they don’t have moats.

Contrarian: Why This IPO Could Be a Disaster in Disguise

The narrative is that Iluvatar is a plucky underdog fighting the American tech monopoly. The contrarian truth is that Iluvatar is a zombie company kept alive by state dollars and a single customer. If ByteDance reduces orders—even by 20%—the company will struggle to cover its $300 million annual burn rate. The IPO may be a “last chance” for early investors to exit before the inevitable.

Consider the parallels to the 2020 DeFi summer, when protocols raised billions on the promise of “financial sovereignty,” only to collapse when liquidity fled. I saw that pattern firsthand as I co-founded GoverningDAO, helping retail users understand risk. The same dynamic applies here: investors are buying a narrative, not a sustainable business. Iluvatar’s price-to-sales ratio could be 50x or more if it only generates $100 million in revenue. That’s not a growth stock; that’s a lottery ticket.

Moreover, the competitive landscape is brutal. Huawei’s Ascend series has a mature ecosystem (CANN + MindSpore), government connections, and unlimited R&D budget. Cambricon and Hygon are also battling for the same state contracts. Iluvatar is the third or fourth player in a two-horse race. The Chinese government will likely consolidate the industry, leaving only one or two GPU giants. Iluvatar is the most likely acquisition target—not the winner.

Then there’s the geopolitical time bomb. If the U.S. tightens sanctions further—for example, by restricting HBM memory or targeting SMIC—Iluvatar could be completely cut off from production. The company has no hedge. It’s a Fabless firm with no foundry, no materials, and no domestic EUV. It is a design house floating on a sea of hope.

Empathy is the ultimate security layer. I feel for the engineers who poured their hearts into this chip, only to be blocked by politics. But in bear markets, trust is earned, not given. Iluvatar hasn’t earned it yet.

Takeaway: The Bellwether for Chinese Tech Independence

This IPO is not just about one company. It’s a test of whether the Chinese capital markets can incubate advanced semiconductor firms under sanctions. If Iluvatar’s stock price soars, it will trigger a wave of similar listings from other sanctioned chip firms—all competing for the same limited pool of domestic demand. If it flops, it could freeze the sector for years.

From a governance perspective, I see a classic principal-agent problem: the Chinese state wants national champions, but individual investors want returns. The two rarely align. Iluvatar must prove it can generate cash from customers other than ByteDance, develop a software ecosystem that developers love, and navigate the trade war without collapsing. That’s a tall order for an $800 million check.

People first, protocol second. The protocol here is the semiconductor supply chain, and it’s broken for anyone not named NVIDIA. Iluvatar’s IPO is a bet that human ingenuity can fix it. But ingenuity alone doesn’t build a moat. Trust is earned in bear markets, and Iluvatar has a long way to go before I’d put my conviction behind it.

As I’ve written in my DAO governance manifestos, “Code is law, but humans are the judges.” The code here is the chip architecture. The judges are the market and the U.S. government. I’m not convinced the verdict will be kind.